Tegsedi
Drug Neurology
NDC 72126-007-01
General payments
$1,876,051
Research payments
$1,830,192
Through program year 2025, $1,876,051 in general payments and $1,830,192 in research payments were reported against Tegsedi (Neurology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $68,854 | 1 |
| 2023 | Research | $238,088 | 81 |
| 2022 | Research | $337,305 | 38 |
| 2021 | General | $154,526 | 1,174 |
| 2021 | Research | $382,080 | 11 |
| 2020 | General | $450,292 | 2,986 |
| 2020 | Research | $648,860 | 16 |
| 2019 | General | $1,271,232 | 4,923 |
| 2019 | Research | $155,005 | 10 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.
The top 5 of 55 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 41 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
9,083 general · 157 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.